JP2018535668A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535668A5
JP2018535668A5 JP2018519710A JP2018519710A JP2018535668A5 JP 2018535668 A5 JP2018535668 A5 JP 2018535668A5 JP 2018519710 A JP2018519710 A JP 2018519710A JP 2018519710 A JP2018519710 A JP 2018519710A JP 2018535668 A5 JP2018535668 A5 JP 2018535668A5
Authority
JP
Japan
Prior art keywords
seq
antigen recognition
recognition construct
tcr
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018519710A
Other languages
English (en)
Japanese (ja)
Other versions
JP7000315B2 (ja
JP2018535668A (ja
Filing date
Publication date
Priority claimed from EP15190230.1A external-priority patent/EP3156067A1/en
Application filed filed Critical
Publication of JP2018535668A publication Critical patent/JP2018535668A/ja
Publication of JP2018535668A5 publication Critical patent/JP2018535668A5/ja
Application granted granted Critical
Publication of JP7000315B2 publication Critical patent/JP7000315B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018519710A 2015-10-16 2016-10-13 高結合活性hpv t細胞受容体 Expired - Fee Related JP7000315B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15190230.1A EP3156067A1 (en) 2015-10-16 2015-10-16 High avidity hpv t-cell receptors
EP15190230.1 2015-10-16
PCT/EP2016/074612 WO2017064198A1 (en) 2015-10-16 2016-10-13 High avidity hpv t-cell receptors

Publications (3)

Publication Number Publication Date
JP2018535668A JP2018535668A (ja) 2018-12-06
JP2018535668A5 true JP2018535668A5 (OSRAM) 2019-11-21
JP7000315B2 JP7000315B2 (ja) 2022-02-04

Family

ID=54359849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018519710A Expired - Fee Related JP7000315B2 (ja) 2015-10-16 2016-10-13 高結合活性hpv t細胞受容体

Country Status (7)

Country Link
US (1) US11401316B2 (OSRAM)
EP (2) EP3156067A1 (OSRAM)
JP (1) JP7000315B2 (OSRAM)
CN (1) CN108135998B (OSRAM)
AU (1) AU2016336817C1 (OSRAM)
CA (1) CA3001395A1 (OSRAM)
WO (1) WO2017064198A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017096329A1 (en) 2015-12-03 2017-06-08 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
DE102017114737A1 (de) 2017-06-30 2019-01-03 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
WO2019070541A1 (en) 2017-10-03 2019-04-11 Juno Therapeutics, Inc. HPV-SPECIFIC BINDING MOLECULES
CN109053879B (zh) * 2018-08-22 2020-12-25 深圳市宝安区中心医院 一种治疗宫颈癌的scFv抗体及其应用
WO2020214957A1 (en) 2019-04-19 2020-10-22 Tcrcure Biopharma Corp. Anti-pd-1 antibodies and uses thereof
CN113072635B (zh) * 2020-01-06 2023-08-25 香雪生命科学技术(广东)有限公司 一种识别hpv抗原的t细胞受体及其编码序列
WO2021155518A1 (en) * 2020-02-05 2021-08-12 Tcrcure Biopharma Corp Anti-hpv t cell receptors and engineered cells
CN113321726B (zh) * 2020-02-28 2024-05-28 香雪生命科学技术(广东)有限公司 一种识别hpv的t细胞受体
EP4125949A4 (en) * 2020-03-23 2024-05-22 The Council of the Queensland Institute of Medical Research Compositions and methods for targeting hpv-infected cells
CN116096740A (zh) * 2020-06-09 2023-05-09 得克萨斯州大学系统董事会 经改造t细胞受体和使用方法
WO2022060904A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
CN114539385A (zh) * 2020-11-26 2022-05-27 香雪生命科学技术(广东)有限公司 一种识别hpv抗原的tcr
CN114853878A (zh) * 2021-02-03 2022-08-05 香雪生命科学技术(广东)有限公司 一种针对hpv的高亲和力tcr
US20240108654A1 (en) 2021-03-03 2024-04-04 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
WO2023014337A1 (en) * 2021-08-04 2023-02-09 GUERRERO PRESTON Rafael Viral and host biomarkers for early detection, therapeutic effectiveness, and relapse monitoring of cancer linked to severe acute respiratory syndrome coronavirus 2 and human papilloma virus
CN116262779A (zh) * 2021-12-14 2023-06-16 深圳先进技术研究院 一种单细胞筛选鉴定人乳头瘤病毒特异性tcr的方法
CN117402232A (zh) * 2022-05-10 2024-01-16 广州医科大学 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr
CN115286690B (zh) * 2022-05-10 2023-06-20 广州医科大学 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr
JP2025531850A (ja) 2022-09-08 2025-09-25 ジュノー セラピューティクス インコーポレイテッド T細胞療法および継続的または間欠的dgk阻害剤投薬の組合せ
GB202311170D0 (en) * 2023-07-20 2023-09-06 Univ Oxford Innovation Ltd Antigen binding polypeptides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
JP2004511425A (ja) 2000-02-08 2004-04-15 ザ ペン ステート リサーチ ファウンデーション 免疫療法に使用されるインターロイキン13受容体サブユニットアルファー2
US20070218080A1 (en) 2006-03-14 2007-09-20 Mackay Memorial Hospital Peptide antigen of human papillomavirus type 16 and application thereof
AU2008304555A1 (en) * 2007-09-25 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified T cell receptors and related materials and methods
EP2618835B1 (en) * 2010-09-20 2017-07-05 BioNTech Cell & Gene Therapies GmbH Antigen-specific t cell receptors and t cell epitopes
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
EP2802356A1 (en) 2012-01-13 2014-11-19 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
US20150175683A1 (en) 2012-06-26 2015-06-25 Apo-T B.V. Binding molecules targeting pathogens
AU2014290288B2 (en) * 2013-07-15 2018-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human papillomavirus 16 E6 T cell receptors
GB201322430D0 (en) * 2013-12-18 2014-02-05 Immunocore Ltd T cell receptors
US10202640B2 (en) * 2014-05-07 2019-02-12 The Board Of Trustees Of The Leland Stanford Junior University Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing

Similar Documents

Publication Publication Date Title
JP2018535668A5 (OSRAM)
JP2016505635A5 (OSRAM)
JP6913032B2 (ja) 共通ネオ抗原
CN105384825B (zh) 一种基于单域抗体的双特异性嵌合抗原受体及其应用
PH12019501241A1 (en) Novel t cell receptors and immune therapy using the same
US20220170097A1 (en) Car t cell transcriptional atlas
CA3045233A1 (en) Novel t cell receptors and immune therapy using the same
MX2023003463A (es) Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame.
PH12020550600A1 (en) Novel engineered t cell receptors and immune therapy using the same
JP2019511222A5 (OSRAM)
JP2020500523A5 (OSRAM)
WO2018172533A3 (en) T cell receptors and immune therapy using the same against prame positive cancers
JP2018509163A5 (OSRAM)
FI3250592T3 (fi) Transtyretiinin vastaisia vasta-aineita
CN108299561A (zh) 一种pd-1纳米抗体及其克隆表达方法与应用
Soong et al. Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors
WO2021247534A2 (en) Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopes
JP2016520053A5 (OSRAM)
Ligtenberg et al. Cripto-1 vaccination elicits protective immunity against metastatic melanoma
JP2014139185A5 (OSRAM)
CN101643497A (zh) Lmp2a蛋白来源的hla-a2限制性表位多肽及其用途
CN113754756B (zh) 一种识别hla-a*02:01/e629-38的tcr及其应用
CN102250244A (zh) 人源抗人催乳素受体抗体及其应用
EP3635098B1 (en) T-cells modified to overexpress phf19
CN103524625B (zh) 一种新型诱导抗体产生的方法